Elastrin Therapeutics � DESTINED

Elastrin Therapeutics, directed by CEO Matthias Breugelmans, has developed a patented nanoparticle therapy that it is hoped can be used to rejuvenate blood vessels through the targeted delivery of active agents. The therapy uses nanoparticles that are conjugated with antibodies that specifically bind to damaged elastin in the tissue. This targeted delivery allows the nanoparticle to effectively deliver active agents such as EDTA and PGG. EDTA helps to decalcify the tissue while PGG promotes the formation of new, healthy elastin.